1
|
França LC, Fontes-Dantas FL, Garcia DG, de Araújo AD, da Costa Gonçalves JP, Rêgo CCDS, da Silva EV, do Nascimento OJM, Lopes FCR, Herlinger AL, de Aguiar RS, da Costa Ferreira Junior O, Figueira FFA, de Souza JPBM, De Mesquita JF, Alves-Leon SV. Molecular mimicry between Zika virus and central nervous system inflammatory demyelinating disorders: the role of NS5 Zika virus epitope and PLP autoantigens. ARQUIVOS DE NEURO-PSIQUIATRIA 2023; 81:357-368. [PMID: 37160141 PMCID: PMC10169219 DOI: 10.1055/s-0043-1768698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Accepted: 12/16/2022] [Indexed: 05/11/2023]
Abstract
BACKGROUND Evidence indicates a strong link between Zika virus (ZikV) and neurological complications. Acute myelitis, optic neuritis, polyneuropathy, and encephalomyelitis that mimic inflammatory idiopathic demyelination disorders (IIDD) after ZikV infection have been reported in Brazil. OBJECTIVE The present study aims to investigate the possible occurrence of molecular mimicry between ZikV antigens and Multiple Sclerosis (MS) autoantigens, the most frequent IIDD of the central nervous system (CNS). METHODS A retrospective cohort study with 305 patients admitted due to suspected arbovirus infection in Rio de Janeiro was performed, all subjects were submitted to neurological examination, and a biological sample was collected for serologic and molecular diagnostic. Bioinformatics tools were used to analyze the peptides shared between ZikV antigens and MS autoantigens. RESULTS Of 305 patients, twenty-six were positive for ZikV and 4 presented IDD patterns found in MS cases. Sequence homology comparisons by bioinformatics approach between NS5 ZikV and PLP MS protein revealed a homology of 5/6 consecutive amino acids (CSSVPV/CSAVPV) with 83% identity, deducing a molecular mimicry. Analysis of the 3D structures revealed a similar conformation with alpha helix presentation. CONCLUSIONS Molecular mimicry between NS5 Zika virus antigen and PLP MS autoantigens emerge as a possible mechanism for IDD spectrum in genetically susceptible individuals.
Collapse
Affiliation(s)
- Laise Carolina França
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | - Fabrícia Lima Fontes-Dantas
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
- Universidade do Estado do Rio de Janeiro, Departamento de Farmacologia e Psicobiologia, Rio de Janeiro RJ, Brazil.
| | - Diogo Gomes Garcia
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | - Amanda Dutra de Araújo
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | - João Paulo da Costa Gonçalves
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | - Cláudia Cecília da Silva Rêgo
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | - Elielson Veloso da Silva
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
| | | | - Fernanda Cristina Rueda Lopes
- Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Departamento de Radiologia, Niterói RJ, Brazil.
| | - Alice Laschuk Herlinger
- Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Departamento de Radiologia, Niterói RJ, Brazil.
| | - Renato Santana de Aguiar
- Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Departamento de Radiologia, Niterói RJ, Brazil.
| | | | | | - Jorge Paes Barreto Marcondes de Souza
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
- Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Departamento de Neurocirurgia, Rio de Janeiro RJ, Brazil.
| | - Joelma Freire De Mesquita
- Universidade Federal do Estado do Rio de Janeiro, Departamento de Genética e Biologia Molecular, Grupo de Bioinformática e Biologia Computacional, Rio de Janeiro RJ, Brazil.
| | - Soniza Vieira Alves-Leon
- Universidade Federal do Estado do Rio de Janeiro, Programa de Pós-Graduação em Neurologia, Laboratório de Neurociências Translacional, Rio de Janeiro RJ, Brazil.
- Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Referência e Pesquisa em Esclerose Múltipla e Outras Doenças Desmielinizantes Inflamatórias Idiopáticas do SNC, Rio de Janeiro RJ, Brazil.
| |
Collapse
|
2
|
Beecham AH, Amezcua L, Chinea A, Manrique CP, Gomez L, Martinez A, Beecham GW, Patsopoulos NA, Chitnis T, Weiner HL, De Jager PL, Burchard EG, Lund BT, Fitzgerald KC, Calabresi PA, Delgado SR, Oksenberg JR, McCauley JL. Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population. PLoS One 2022; 17:e0279132. [PMID: 36548255 PMCID: PMC9778564 DOI: 10.1371/journal.pone.0279132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 11/29/2022] [Indexed: 12/24/2022] Open
Abstract
The Major Histocompatibility Complex (MHC) makes the largest genetic contribution to multiple sclerosis (MS) susceptibility, with 32 independent effects across the region explaining 20% of the heritability in European populations. Variation is high across populations with allele frequency differences and population-specific risk alleles identified. We sought to identify MHC-specific MS susceptibility variants and assess the effect of ancestral risk modification within 2652 Latinx and Hispanic individuals as well as 2435 Black and African American individuals. We have identified several novel susceptibility alleles which are rare in European populations including HLA-B*53:01, and we have utilized the differing linkage disequilibrium patterns inherent to these populations to identify an independent role for HLA-DRB1*15:01 and HLA-DQB1*06:02 on MS risk. We found a decrease in Native American ancestry in MS cases vs controls across the MHC, peaking near the previously identified MICB locus with a decrease of ~5.5% in Hispanics and ~0.4% in African Americans. We have identified several susceptibility variants, including within the MICB gene region, which show global ancestry risk modification and indicate ancestral differences which may be due in part to correlated environmental factors. We have also identified several susceptibility variants for which MS risk is modified by local ancestry and indicate true ancestral genetic differences; including HLA-DQB1*06:02 for which MS risk for European allele carriers is almost two times the risk for African allele carriers. These results validate the importance of investigating MS susceptibility at an ancestral level and offer insight into the epidemiology of MS phenotypic diversity.
Collapse
Affiliation(s)
- Ashley H. Beecham
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
- Dr. John T. Macdonald Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| | - Lilyana Amezcua
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America
| | - Angel Chinea
- San Juan MS Center, Guaynabo, Puerto Rico, United States of America
| | - Clara P. Manrique
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| | - Lissette Gomez
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| | - Andrea Martinez
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America
| | - Gary W. Beecham
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
- Dr. John T. Macdonald Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| | - Nikolaos A. Patsopoulos
- Ann Romney Center for Neurological Diseases, Brigham and Women’s Hospital, Boston, MA, United States of America
| | - Tanuja Chitnis
- Ann Romney Center for Neurological Diseases, Brigham and Women’s Hospital, Boston, MA, United States of America
| | - Howard L. Weiner
- Ann Romney Center for Neurological Diseases, Brigham and Women’s Hospital, Boston, MA, United States of America
| | - Philip L. De Jager
- Center For Translational & Computational Neuroimmunology and the Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, United States of America
| | - Esteban G. Burchard
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States of America
| | - Brett T. Lund
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America
| | - Kathryn C. Fitzgerald
- Department of Neurology and The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America
| | - Peter A. Calabresi
- Department of Neurology and The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America
| | - Silvia R. Delgado
- Multiple Sclerosis Division, Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| | - Jorge R. Oksenberg
- Department of Neurology, University of California, San Francisco, San Francisco, CA, United States of America
| | - Jacob L. McCauley
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
- Dr. John T. Macdonald Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, United States of America
| |
Collapse
|
3
|
Noro F, Alves-Leon SV, Fontes-Dantas FL, Valle Bahia PR, Andreiuolo RF, Rueda Lopes FC, Pereira VCSR, Abi-Haila LDAA, Coutinho RA, Araujo ADD, Marchiori E. HLA-DQA1*04:01 is related to a higher multiple sclerosis lesion load on T2/Flair MRI sequences. ARQUIVOS DE NEURO-PSIQUIATRIA 2021; 79:1109-1115. [PMID: 34877984 DOI: 10.1590/0004-282x-anp-2020-0487] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 12/23/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND The genetic predisposition to multiple sclerosis (MS) is associated with HLA alleles, especially HLA-DRB1*15:01. OBJECTIVE To identify associations between findings in magnetic resonance imaging (MRI) and genetic features in a Brazilian cohort of patients with MS. METHODS We retrospectively studied data from 95 consecutive patients with MS. Two independent observers who were blinded to the clinical data identified black holes and enhanced lesions on T1 MRI sequences, and counted and measured contrast-enhanced lesions on T2 and Flair (fluid attenuation inversion recovery) sequences. Cases were classified according to lesion size, number, and volume. The HLA-DRB1, HLA-DQB1, and HLA-DQA1 alleles, and the rs4774, rs3087456, rs6897932, rs731236, and rs1033182 single nucleotide polymorphisms were identified by polymerase chain reaction amplification with sequence-specific primers using the One Lambda Inc. Kit, Canoga Park, CA, USA. RESULTS Patients with the HLA-DQA1*04:01 allele had lesion load (adjusted for age, sex, and MS duration) above median compared with patients with other HLA-DQA1 alleles (p=0.02). There were no differences among all the other HLA alleles and single nucleotide polymorphisms and lesion load. CONCLUSIONS The correlation of the HLA-DQA1*04:01 allele with a higher lesion load on T2/Flair MRI sequences suggests that the presence of this allele is associated with the risk of greater MS severity.
Collapse
Affiliation(s)
- Fabio Noro
- Universidade Federal do Rio de Janeiro, Departamento de Radiologia, Rio de Janeiro RJ, Brazil
| | | | | | | | | | | | | | | | - Renan Amaral Coutinho
- Universidade Federal do Rio de Janeiro, Departamento de Radiologia, Rio de Janeiro RJ, Brazil
| | - Amanda Dutra de Araujo
- Universidade Federal do Rio de Janeiro, Departamento de Radiologia, Rio de Janeiro RJ, Brazil
| | - Edson Marchiori
- Universidade Federal do Rio de Janeiro, Departamento de Radiologia, Rio de Janeiro RJ, Brazil
| |
Collapse
|
4
|
Beecham AH, Amezcua L, Chinea A, Manrique CP, Rubi C, Isobe N, Lund BT, Santaniello A, Beecham GW, Burchard EG, Comabella M, Patsopoulos N, Fitzgerald K, Calabresi PA, De Jager P, Conti DV, Delgado SR, Oksenberg JR, McCauley JL. The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. Mult Scler 2020; 26:1329-1339. [PMID: 31368393 PMCID: PMC6994382 DOI: 10.1177/1352458519863764] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Substantial progress has been made toward unraveling the genetic architecture of multiple sclerosis (MS) within populations of European ancestry, but few genetic studies have focused on Hispanic and African American populations within the United States. OBJECTIVE We sought to test the relevance of common European MS risk variants outside of the major histocompatibility complex (n = 200) within these populations. METHODS Genotype data were available on 2652 Hispanics (1298 with MS, 1354 controls) and 2435 African Americans (1298 with MS, 1137 controls). We conducted single variant, pathway, and cumulative genetic risk score analyses. RESULTS We found less replication than statistical power suggested, particularly among African Americans. This could be due to limited correlation between the tested and causal variants within the sample or alternatively could indicate allelic and locus heterogeneity. Differences were observed between pathways enriched among the replicating versus all 200 variants. Although these differences should be examined in larger samples, a potential role exists for gene-environment or gene-gene interactions which alter phenotype differentially across racial and ethnic groups. Cumulative genetic risk scores were associated with MS within each study sample but showed limited diagnostic capability. CONCLUSION These findings provide a framework for fine-mapping efforts in multi-ethnic populations of MS.
Collapse
Affiliation(s)
- A H Beecham
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA/The Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - L Amezcua
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - A Chinea
- San Juan MS Center, Guaynabo, Puerto Rico, USA; Universidad Central del Caribe, Bayamon, Puerto Rico, USA
| | - C P Manrique
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - C Rubi
- San Juan MS Center, Guaynabo, Puerto Rico, USA; Universidad Central del Caribe, Bayamon, Puerto Rico, USA
| | - N Isobe
- Department of Neurological Therapeutics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - B T Lund
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - A Santaniello
- Department of Neurology, University of California at San Francisco, San Francisco, CA, USA
| | - G W Beecham
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA/The Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - E G Burchard
- Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA
| | - M Comabella
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - N Patsopoulos
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - K Fitzgerald
- Department of Neurology and The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - P A Calabresi
- Department of Neurology and The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - P De Jager
- Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA
| | - D V Conti
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - S R Delgado
- Multiple Sclerosis Division, Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - J R Oksenberg
- Department of Neurology, University of California at San Francisco, San Francisco, CA, USA
| | - J L McCauley
- John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA/The Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA
| |
Collapse
|
5
|
Katsavos S, Artemiadis A, Gontika M, Skarlis C, Markoglou N, Davaki P, Stamboulis E, Kilindireas K, Stefanis L, Anagnostouli M. HLA-DRB1 differences in allelic distribution between familial and sporadic multiple sclerosis in a Hellenic cohort. Postgrad Med 2019; 131:490-495. [DOI: 10.1080/00325481.2019.1655382] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Serafeim Katsavos
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Artemios Artemiadis
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
- Medical School, University of Cyprus, Nicosia, Cyprus
| | - Maria Gontika
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Charalampos Skarlis
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Nikolaos Markoglou
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Panagiota Davaki
- Demyelinating Diseases Clinic, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Eleftherios Stamboulis
- 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Konstantinos Kilindireas
- Demyelinating Diseases Clinic, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Leonidas Stefanis
- 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| | - Maria Anagnostouli
- Immunogenetics Laboratory, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
- Demyelinating Diseases Clinic, 1st Dept of Neurology, Medical School, National and Kapodistrian University of Athens, NKUA, Aeginition Hospital, Athens, Greece
| |
Collapse
|
6
|
Pereira VCSR, Fontes-Dantas FL, Paradela ER, Malfetano FR, Scherpenhuijzen SDSB, Mansur LF, Luiz RR, Oliveira APD, Farinhas JGD, Maiolino Â, Alves-Leon SV. Polymorphisms in the CIITA -168A/G (rs3087456) and CIITA +1614G/C (rs4774) may influence severity in multiple sclerosis patients. ARQUIVOS DE NEURO-PSIQUIATRIA 2019; 77:166-173. [PMID: 30970129 DOI: 10.1590/0004-282x20190026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Accepted: 11/29/2018] [Indexed: 02/03/2023]
Abstract
It is currently unknown how genetic factors may influence the clinical course of multiple sclerosis (MS). OBJECTIVE We examined the impact of CIITA polymorphisms -168A/G (rs3087456) and +1614G/C (rs4774) on the risk of disability progression, severity and on responses to first-line immunomodulator treatments. METHODS Genomic DNA was extracted from blood samples. We used ABI3730xl and GeneMapper v.4.0 software to identify genotype variations. All patients were followed up and clinically reassessed at three-month intervals. Disability progression was measured by the Expanded Disability Status Scale and disease severity by the Multiple Sclerosis Spasticity Scale (MSSS). RESULTS We included 37 men and 80 women. We found no evidence regarding the influence of the single nucleotide polymorphisms studied in the Expanded Disability Status Scale or therapeutic response of the evaluated drugs. We performed a logistic regression analysis with the MSSS and found that a less severe MS course was associated with wild type CIITA -168AA and CIITA +1614GG, as the chance of the patient progressing to MSSS2 and MSSS3 decreased in 61% and 75% with CIITA -168AA and 66% and 75% with CIITA +1614GG, respectively (p < 0.0001). Although less significant, the CIITA +1614 GC also pointed to a less severe MS course and the chance of the patient progressing to MSSS3 decreased 79% (p = 0.015). We also observed that the CIITA -168GG genotype was more frequent in MSSS2 and MSSS3 and had 40% lower odds ratio to becoming more severe MS. CONCLUSION These data suggest that CIITA -168AA, CIITA +1614GG and CIITA +1614 GC polymorphisms may be associated with a better MS clinical course. This knowledge may be useful for a better understanding of MS and its therapeutic management.
Collapse
Affiliation(s)
| | - Fabrícia Lima Fontes-Dantas
- Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| | - Eduardo Ribeiro Paradela
- Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| | | | | | - Letícia Fêzer Mansur
- Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| | - Ronir Raggio Luiz
- Universidade Federal do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
| | - André Peres De Oliveira
- Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| | - João Gabriel Dib Farinhas
- Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| | - Ângelo Maiolino
- Universidade Federal do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
| | - Soniza Vieira Alves-Leon
- Universidade Federal do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil.,Universidade Federal do Estado do Rio de Janeiro, Laboratório de Neurociências Translacional, Programa de Pós-Graduação em Neurologia, Rio de Janeiro RJ, Brasil
| |
Collapse
|
7
|
da Silva Bernardes M, Antão Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, Ferreira Pereira F, Vasconcelos CC, Papais Alvarenga RM. Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease? J Neuroimmunol 2019; 330:74-80. [PMID: 30836273 DOI: 10.1016/j.jneuroim.2019.02.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 01/20/2019] [Accepted: 02/13/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND The HLA-DR15 extended haplotype HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 comprises the strongest genetic risk factor for multiple sclerosis (MS). The aim of this work was to investigate whether HLA-DR15 alleles were significantly associated with the susceptibility to MS familial forms (MSf) in an admixed Brazilian population. METHODS Association analyses between DR15 and the clinical and demographic variables were made. RESULTS We have genotyped 25 familial cases. The DR15 was detected in 11/25 (44%) of them and in none of controls (P < .00001). DR15 was significantly associated to a foreign ancestor background (P = .029) and later age of onset (P = .018).
Collapse
Affiliation(s)
- Melina da Silva Bernardes
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil.
| | - Carmen Lucia Antão Paiva
- Department of Genetics and Molecular Biology, Instituto Biomédico, Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Frei Caneca 94, Rio de Janeiro/RJ 20211-040, Brazil
| | - Eduardo Ribeiro Paradela
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil
| | - Marcos Papais Alvarenga
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil; Department of Neurology, Hospital da Lagoa, Ministry of Health, Rua Jardim Botânico 501, Rio de Janeiro/RJ 22470-050, Brazil
| | - Fernanda Ferreira Pereira
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil
| | - Claudia Cristina Vasconcelos
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil; Department of Neurology, Hospital da Lagoa, Ministry of Health, Rua Jardim Botânico 501, Rio de Janeiro/RJ 22470-050, Brazil
| | - Regina Maria Papais Alvarenga
- Graduate Progam in Neurology (PPGNEURO), Hospital Universitário Gaffrée e Guinle (HUGG), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, Rio de Janeiro/RJ 20270-004, Brazil; Department of Neurology, Hospital da Lagoa, Ministry of Health, Rua Jardim Botânico 501, Rio de Janeiro/RJ 22470-050, Brazil
| |
Collapse
|
8
|
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka. Mult Scler Int 2018; 2018:5342936. [PMID: 29682349 PMCID: PMC5851020 DOI: 10.1155/2018/5342936] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Revised: 01/29/2018] [Accepted: 02/06/2018] [Indexed: 12/29/2022] Open
Abstract
Multiple sclerosis (MS) is a heterogeneous disease which is poorly studied in Asia, where the disease is known to be rare with significant differences in clinical and radiological presentations and intrathecal antibody response. Therefore the objective of this study was to determine clinical presentation, radiological and neurophysiological characteristics, and oligoclonal band status in Sri Lankan MS patients, following careful exclusion of patients with neuromyelitis optica spectrum disorders and other conditions mimicking multiple sclerosis. Sixty-nine MS patients were recruited to the study adhering to McDonald 2010 criteria. Their clinical presentation, characteristics of central nervous system lesions in magnetic resonance imaging, visual evoked potential (VEP) results, oligoclonal bands (OCB), and AQP4 antibody status were studied. Of 69 MS patients, 54%, 6%, and 1% were relapsing remitting, secondary progressive, and primary progressive, respectively, and 39% were patients with clinically isolated syndrome. The commonest clinical presentations were cerebral motor followed by cerebral sensory and optic neuritis. Majority had typical periventricular and infratentorial lesions in MRI. Though not clinically apparent, bilateral delay of P100 wave latency was present in 52%. OCB positivity was 42% and AQP4 antibody was positive in only one patient. In conclusion, this group of Sri Lankan MS patients shares most of the clinical and radiological features of Caucasian MS patients. However, the OCB positivity is lower in this group, when compared to the Caucasian MS populations.
Collapse
|
9
|
Hashemi S, Fernandez Martinez JL, Saligan L, Sonis S. Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. J Pain Symptom Manage 2017; 54:326-339. [PMID: 28797855 DOI: 10.1016/j.jpainsymman.2017.04.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 03/23/2017] [Accepted: 04/13/2017] [Indexed: 12/16/2022]
Abstract
CONTEXT Despite numerous proposed mechanisms, no definitive pathophysiology underlying radiotherapy-induced fatigue (RIF) has been established. However, the dysregulation of a set of 35 genes was recently validated to predict development of fatigue in prostate cancer patients receiving radiotherapy. OBJECTIVES To hypothesize novel pathways, and provide genetic targets for currently proposed pathways implicated in RIF development through analysis of the previously validated gene set. METHODS The gene set was analyzed for all phenotypic attributions implicated in the phenotype of fatigue. Initially, a "directed" approach was used by querying specific fatigue-related sub-phenotypes against all known phenotypic attributions of the gene set. Then, an "undirected" approach, reviewing the entirety of the literature referencing the 35 genes, was used to increase analysis sensitivity. RESULTS The dysregulated genes attribute to neural, immunological, mitochondrial, muscular, and metabolic pathways. In addition, certain genes suggest phenotypes not previously emphasized in the context of RIF, such as ionizing radiation sensitivity, DNA damage, and altered DNA repair frequency. Several genes also associated with prostate cancer depression, possibly emphasizing variable radiosensitivity by RIF-prone patients, which may have palliative care implications. Despite the relevant findings, many of the 35 RIF-predictive genes are poorly characterized, warranting their investigation. CONCLUSION The implications of herein presented RIF pathways are purely theoretical until specific end-point driven experiments are conducted in more congruent contexts. Nevertheless, the presented attributions are informative, directing future investigation to definitively elucidate RIF's pathoetiology. This study demonstrates an arguably comprehensive method of approaching known differential expression underlying a complex phenotype, to correlate feasible pathophysiology.
Collapse
Affiliation(s)
- Sepehr Hashemi
- Harvard School of Dental Medicine, Boston, Massachusetts, USA
| | | | - Leorey Saligan
- National Institutes of Health, National Institute of Nursing Research, Bethesda, Maryland, USA
| | - Stephen Sonis
- Harvard School of Dental Medicine, Boston, Massachusetts, USA; Biomodels LLC, Watertown, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA.
| |
Collapse
|
10
|
Amezcua L. MS in self-identified Hispanic/Latino individuals living in the US. Mult Scler J Exp Transl Clin 2017; 3:2055217317725103. [PMID: 28979795 PMCID: PMC5617095 DOI: 10.1177/2055217317725103] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2017] [Accepted: 07/07/2017] [Indexed: 12/26/2022] Open
Abstract
Self-identified Hispanic/Latino individuals living with multiple sclerosis (MS) in the continental United States (US) are a diverse group that represents different cultural and ancestral backgrounds. A marked variability in the way MS affects various subgroups of Hispanics in the US has been observed. We reviewed and synthesized available data about MS in Hispanics in the US. There are likely a host of multifactorial elements contributing to these observations that could be explained by genetic, environmental, and social underpinnings. Barriers to adequate MS care in Hispanics are likely to include delivery of culturally competent care and social and economic disadvantages. Considerable efforts, including the formation of a national consortium known as the Alliance for Research in Hispanic Multiple Sclerosis (ARHMS), are underway to help further explore these various factors.
Collapse
Affiliation(s)
- Lilyana Amezcua
- Department of Neurology, University of Southern California, Keck School of Medicine, USA
| |
Collapse
|
11
|
|
12
|
Correale J, Farez MF, Gaitán MI. Environmental factors influencing multiple sclerosis in Latin America. Mult Scler J Exp Transl Clin 2017. [PMID: 28638627 PMCID: PMC5472234 DOI: 10.1177/2055217317715049] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
It is generally accepted that autoimmune diseases like multiple sclerosis (MS) arise from complex interactions between genetic susceptibility and environmental factors. Genetic variants confer predisposition to develop MS, but cannot be therapeutically modified. On the other hand, several studies have shown that different lifestyle and environmental factors influence disease development, as well as activity levels and progression. Unlike genetic risk factors, these can be modified, with potential for prevention, particularly in high-risk populations. Most studies identifying particular lifestyle and environmental factors have been carried out in Caucasian patients with MS. Little or no data is available on the behavior of these factors in Latin American populations. Ethnic and geographic differences between Latin America and other world regions suggest potential regional variations in MS, at least with respect to some of these factors. Furthermore, particular environmental characteristics observed more frequently in Latin America could explain regional differences in MS prevalence. Site-specific studies exploring influences of local environmental factors are warranted.
Collapse
Affiliation(s)
- Jorge Correale
- Department of Neurology, Institute for Neurological Research Dr Raúl Carrea, FLENI, Buenos Aires, Argentina
| | - Mauricio F Farez
- Department of Neurology, Institute for Neurological Research Dr Raúl Carrea, FLENI, Buenos Aires, Argentina
| | - María Inés Gaitán
- Center for Research on Neuroimmunological Diseases (CIEN) from the Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina
| |
Collapse
|
13
|
Werneck LC, Lorenzoni PJ, Arndt RC, Kay CSK, Scola RH. The immunogenetics of multiple sclerosis. The frequency of HLA-alleles class 1 and 2 is lower in Southern Brazil than in the European population. ARQUIVOS DE NEURO-PSIQUIATRIA 2016; 74:607-16. [DOI: 10.1590/0004-282x20160100] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Accepted: 05/25/2016] [Indexed: 11/22/2022]
Abstract
ABSTRACT Objective To study the HLA of class 1and 2 in a multiple sclerosis (MS) population to verify the susceptibility for the disease in the Southern Brazil. Methods We analyzed patients with MS and controls, by direct sequencing of the genes related to HLA DRB1, DQB1, DPB1, A, B and C alleles with high resolution techniques. Results We found a lower frequency of all HLA alleles class 1 and 2 in MS and controls comparing to the European population. Several alleles had statistical correlation, but after Bonferroni correction, the only allele with significance was the HLA-DQB1*02:03, which has a positive association with MS. Conclusions Our data have different frequency of HLA-alleles than the previous published papers in the Southeast Brazil and European population, possible due to several ethnic backgrounds.
Collapse
|
14
|
|
15
|
Toro J, Cuellar-Giraldo D, Díaz-Cruz C, Burbano LE, Guío CM, Reyes S, Cortes F, Cárdenas-Robledo S, Narváez DM, Cárdenas W, Porras A, Lattig MC, Groot de Restrepo H. HLA-DRB1*14 is a protective allele for multiple sclerosis in an admixed Colombian population. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2015; 3:e192. [PMID: 26740965 PMCID: PMC4694072 DOI: 10.1212/nxi.0000000000000192] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Accepted: 11/03/2015] [Indexed: 11/15/2022]
Abstract
OBJECTIVE The aim of this study was to determine ancestry informative markers, mitochondrial DNA haplogroups, and the association between HLA-DRB1 alleles and multiple sclerosis (MS) in a group of patients from Bogotá, Colombia. METHODS In this case-control study, genomic DNA was isolated and purified from blood samples. HLA-DRB1 allele genotyping was done using PCR. Mitochondrial hypervariable region 1 was amplified and haplogroups were determined using HaploGrep software. Genomic ancestry was estimated by genotyping a panel of ancestry informative markers. To test the association of HLA polymorphisms and MS, we ran separate multivariate logistic regression models. Bonferroni correction was used to account for multiple regression tests. RESULTS A total of 100 patients with MS (mean age 40.4 ± 12 years; 70% females) and 200 healthy controls (mean age 37.6 ± 11 years; 83.5% females) were included in the analysis. Ancestry proportions and haplogroup frequencies did not differ between patients and controls. HLA-DRB1*15 was present in 31% of cases and 13.5% of controls, whereas HLA-DRB1*14 was present in 5% of cases and 15.5% of controls. In the multivariate model, HLA-DRB1*15 was significantly associated with MS (odds ratio [OR] = 3.05, p < 0.001), whereas HLA-DRB1*14 was confirmed as a protective factor in our population (OR = 0.16, p = 0.001). CONCLUSIONS This study provides evidence indicating that HLA-DRB1*15 allele confers susceptibility to MS and HLA-DRB1*14 allele exerts resistance to MS in a highly admixed population. This latter finding could partially explain the low prevalence of MS in Bogotá, Colombia.
Collapse
Affiliation(s)
- Jaime Toro
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - David Cuellar-Giraldo
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Camilo Díaz-Cruz
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Lisseth-Estefania Burbano
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Claudia-Marcela Guío
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Saúl Reyes
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Fabián Cortes
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Simón Cárdenas-Robledo
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Diana M Narváez
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Wilmer Cárdenas
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Alexandra Porras
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - María-Claudia Lattig
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| | - Helena Groot de Restrepo
- School of Medicine (J.T., D.C.-G., C.-M.G., S.R., F.C., A.P.), Universidad El Bosque, Bogotá, Colombia; Department of Neurology (J.T., D.C.-G., C.D.-C., L.-E.B., C.-M.G., S.R., S.C.-R.), Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia; and School of Medicine (J.T., D.C.-G., C.D.-C., L.-E.B., S.R., D.M.N., H.G.d.R.) and Human Genetics Laboratory (D.C.-G., D.M.N., W.C., M.-C.L., H.G.d.R.), Department of Biological Sciences, Universidad de Los Andes, Bogotá, Colombia
| |
Collapse
|
16
|
Paradela ER, Alves-Leon SV, Figueiredo ALS, Pereira VCSR, Malfetano F, Mansur LF, Scherpenhuijzen S, Agostinho LA, Rocha CF, Rueda-Lopes F, Gasparetto E, Paiva CLA. The CIITA genetic polymorphism rs4774*C in combination with the HLA-DRB1*15:01 allele as a putative susceptibility factor to multiple sclerosis in Brazilian females. ARQUIVOS DE NEURO-PSIQUIATRIA 2015; 73:283-8. [PMID: 25992516 DOI: 10.1590/0004-282x20150012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 12/09/2014] [Indexed: 11/21/2022]
Abstract
The objective of this study was to investigate the association between the HLA alleles at the DQA1, DQB1 and DRB1 loci, the CIITA genetic polymorphisms -168A/G and +1614G/C, and susceptibility to multiple sclerosis (MS) in a sample from Rio de Janeiro State, Brazil. Furthermore, we wished to determine whether any of these associations might be more significant in women compared with men. DNA samples from 52 relapsing-remitting MS (RRMS) patients and 126 healthy controls matched for sex and age were analyzed. We identified a significant HLA-DRB1*15:01-MS association that was female-specific (Odds Ratio (OR) = 4.78; p = 0.001). Furthermore, we observed that the +1614G/C mutation in combination with the HLA-DRB1*15:01 allele increased susceptibility to MS in females (OR = 4.55; p = 0.01). Together, these findings highlight the polygenic nature of MS.
Collapse
Affiliation(s)
- Eduardo R Paradela
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Soniza V Alves-Leon
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - André L S Figueiredo
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Valéria C S R Pereira
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Fabíola Malfetano
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Letícia F Mansur
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Simone Scherpenhuijzen
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Luciana A Agostinho
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Catielly F Rocha
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Fernanda Rueda-Lopes
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Emerson Gasparetto
- Centro de Referência em Esclerose Múltipla e outras Doenças Inflamatórias Desmielinizantes do Sistema Nervoso Central,, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Carmen L A Paiva
- Departamento de Neurologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| |
Collapse
|
17
|
Abstract
One of the most consistent findings in multiple sclerosis (MS) is that development of MS is linked with carriage of the class II human leucocyte antigen (HLA) molecule HLA-DRB1*15:01; around 60 % of Caucasian MS patients carry this allele compared to 25-30 % of ethnically matched healthy individuals. However, other HLA molecules have also been linked to the development of MS. In this chapter, the association between different HLA types and susceptibility to MS will be reviewed, and other linkages between the carriage of specific HLA molecules and clinical and experimental findings in MS will be considered.
Collapse
Affiliation(s)
- Judith M Greer
- The University of Queensland, UQ Centre for Clinical Research, Building 71/918 Riyal Brisbane and Women's Hospital, Brisbane, QLD, 4029, Australia.
| |
Collapse
|
18
|
Kaushansky N, Ben-Nun A. DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele. Front Oncol 2014; 4:280. [PMID: 25360418 PMCID: PMC4199271 DOI: 10.3389/fonc.2014.00280] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 09/29/2014] [Indexed: 12/20/2022] Open
Abstract
Susceptibility to multiple sclerosis (MS) has been linked mainly to the HLA-DRB1 locus, with the HLA-DR15 haplotype (DRB1*1501-DQA1*0102-DQB1*0602-DRB5*0101) dominating MS risk in Caucasians. Although genes in the HLA-II region, particularly DRB1*1501, DQA1*0102-DQB1*0602, are in tight linkage disequilibrium, genome-wide-association, and gene candidate studies identified the DRB1*15:01 allele as the primary risk factor in MS. Many genetic and immune-functional studies have indicated DRB1*15:01 as a primary risk factor in MS, while only some functional studies suggested a disease-modifying role for the DRB5*01 or DQB1*06 alleles. In this respect, the susceptibility of DRB1*15:01-transgenic (Tg) mice to myelin basic protein- or myelin oligodendrocyte glycoprotein-induced MS-like disease is consistent with primary contribution of DRB1*15:01 to HLA-DR15+ MS. The studies summarized here show that susceptibility to MS-like disease, induced in HLA-“humanized” mice by myelin oligodendrocytic basic protein or by the proteolipid protein, one of the most prominent encephalitogenic target antigens implicated in human MS, is determined by DQB1*06:02, rather than by the DRB1*15:01 allele. These findings not only offer a rationale for a potential role for DQB1*06:02 in predisposing susceptibility to MS, but also suggest a more complex and differential functional role for HLA-DR15 alleles, depending on the primary target myelin antigen. However, the conflict between these findings in HLA-Tg mice and the extensive genome-wide-association studies, which could not detect any significant effect from the DQB1*06:02 allele on MS risk, is rather puzzling. Functional analysis of MS PBLs for DQB1*06:02-associated anti-myelin autoimmunity may indicate whether or not DQB1*06:02 is associated with MS pathogenesis.
Collapse
Affiliation(s)
- Nathali Kaushansky
- Department of Immunology, The Weizmann Institute of Science , Rehovot , Israel
| | - Avraham Ben-Nun
- Department of Immunology, The Weizmann Institute of Science , Rehovot , Israel
| |
Collapse
|
19
|
Abolfazli R, Samadzadeh S, Sabokbar T, Siroos B, Armaki SA, Aslanbeiki B, Ghelman M, Taheri T, Shakoori A. Relationship between HLA-DRB1* 11/15 genotype and susceptibility to multiple sclerosis in IRAN. J Neurol Sci 2014; 345:92-6. [DOI: 10.1016/j.jns.2014.07.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 04/30/2014] [Accepted: 07/07/2014] [Indexed: 01/21/2023]
|
20
|
Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization. J Neurol Sci 2014; 339:196-206. [DOI: 10.1016/j.jns.2014.02.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Accepted: 02/17/2014] [Indexed: 12/13/2022]
|
21
|
Comini-Frota ER, Brum DG, Kaimen-Maciel DR, Fragoso YD, Barreira AA, Donadi EA. Frequency of reported European ancestry among multiple sclerosis patients from four cities in the southern and southeastern regions of Brazil. Clin Neurol Neurosurg 2013; 115:1642-6. [DOI: 10.1016/j.clineuro.2013.02.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Revised: 12/31/2012] [Accepted: 02/16/2013] [Indexed: 11/27/2022]
|
22
|
Pereira VCSR, Malfetano FR, Meira ID, Souza LFD, Liem AM, Maiolino A, Alves-Leon SV. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort. ARQUIVOS DE NEURO-PSIQUIATRIA 2013; 70:774-9. [PMID: 23060103 DOI: 10.1590/s0004-282x2012001000005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Accepted: 06/19/2012] [Indexed: 11/21/2022]
Abstract
INTRODUCTION Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among relapsing-remitting multiple sclerosis (RRMS) patients. METHODS We analyzed treatment response to IFNb and GA in ninety-one RRMS patients followed for at least one year. Clinical response was established by clinical criteria based on relapses, disability progression or both. RESULTS We observed a proportion of nonresponders, ranging from 3.3 to 42.9%, depending on the stringency of the criteria used. CONCLUSIONS Our sample of Brazilian patients with MS has similarities when compared to other studies and there was no statistically significant difference regarding age, gender, ethnicity or disease duration between responders and nonresponders.
Collapse
|
23
|
Toro J, Cárdenas S, Fernando Martínez C, Urrutia J, Díaz C. Multiple sclerosis in Colombia and other Latin American Countries. Mult Scler Relat Disord 2013; 2:80-9. [DOI: 10.1016/j.msard.2012.09.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 08/30/2012] [Accepted: 09/05/2012] [Indexed: 11/29/2022]
|
24
|
Kaushansky N, Altmann DM, David CS, Lassmann H, Ben-Nun A. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). J Neuroinflammation 2012; 9:29. [PMID: 22316121 PMCID: PMC3344688 DOI: 10.1186/1742-2094-9-29] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Accepted: 02/08/2012] [Indexed: 12/20/2022] Open
Abstract
Background Multiple sclerosis (MS) is associated with pathogenic autoimmunity primarily focused on major CNS-myelin target antigens including myelin basic protein (MBP), proteolipidprotein (PLP), myelin oligodendrocyte protein (MOG). MS is a complex trait whereby the HLA genes, particularly class-II genes of HLA-DR15 haplotype, dominate the genetic contribution to disease-risk. Due to strong linkage disequilibrium in HLA-II region, it has been hard to establish precisely whether the functionally relevant effect derives from the DRB1*1501, DQA1*0102-DQB1*0602, or DRB5*0101 loci of HLA-DR15 haplotype, their combinations, or their epistatic interactions. Nevertheless, most genetic studies have indicated DRB1*1501 as a primary risk factor in MS. Here, we used 'HLA-humanized' mice to discern the potential relative contribution of DRB1*1501 and DQB1*0602 alleles to susceptibility to "humanized" MS-like disease induced by PLP, one of the most prominent and encephalitogenic target-antigens implicated in human MS. Methods The HLA-DRB1*1501- and HLA-DQB1*0602-Tg mice (MHC-II-/-), and control non-HLA-DR15-relevant-Tg mice were immunized with a set of overlapping PLP peptides or with recombinant soluble PLP for induction of "humanized" MS-like disease, as well as for ex-vivo analysis of immunogenic/immunodominant HLA-restricted T-cell epitopes and associated cytokine secretion profile. Results PLP autoimmunity in both HLA-DR15-Tg mice was focused on 139-151 and 175-194 epitopes. Strikingly, however, the HLA-DRB1*1501-transgenics were refractory to disease induction by any of the overlapping PLP peptides, while HLA-DQB1*0602 transgenics were susceptible to disease induction by PLP139-151 and PLP175-194 peptides. Although both transgenics responded to both peptides, the PLP139-151- and PLP175-194-reactive T-cells were directed to Th1/Th17 phenotype in DQB1*0602-Tg mice and towards Th2 in DRB1*1501-Tg mice. Conclusions While genome studies map a strong MS susceptibility effect to the region of DRB1*1501, our findings offer a rationale for potential involvement of pathogenic DQ6-associated autoimmunity in MS. Moreover, that DQB1*0602, but not DRB1*1501, determines disease-susceptibility to PLP in HLA-transgenics, suggests a potential differential, functional role for DQB1*0602 as a predisposing allele in MS. This, together with previously demonstrated disease-susceptibility to MBP and MOG in DRB1*1501-transgenics, also suggests a differential role for DRB1*1501 and DQB1*0602 depending on target antigen and imply a potential complex 'genotype/target antigen/phenotype' relationship in MS heterogeneity.
Collapse
Affiliation(s)
- Nathali Kaushansky
- Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
| | | | | | | | | |
Collapse
|
25
|
Lana-Peixoto MA, Frota ERC, Campos GB, Monteiro LP. The prevalence of multiple sclerosis in Belo Horizonte, Brazil. ARQUIVOS DE NEURO-PSIQUIATRIA 2012; 70:102-7. [DOI: 10.1590/s0004-282x2012000200006] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2011] [Accepted: 09/05/2011] [Indexed: 11/22/2022]
Abstract
Investigations on the prevalence rates of multiple sclerosis (MS) around the world have yielded important clues on the interplay between genetic susceptibility and environmental factors. As Brazil is a huge country laid on many latitudes and inhabited by population with distinct ethnic backgrounds, it might be assumed that the frequency of MS varies in its different regions. Objective: To determine the prevalence rate of MS in Belo Horizonte, the capital of the State of Minas Gerais, Southeastern Brazil. Methods: We used six sources to draw up a provisional list of identified cases of MS. Only patients with diagnosis of clinically definite MS according to Poser Committee criteria were included. Results: The calculated crude MS prevalence was 18.1/100,000 inhabitants. Conclusions: The MS prevalence in Belo Horizonte is similar to that found in São Paulo and Botucatu, two other cities in southeastern Brazil with similar ethnic background.
Collapse
|
26
|
Grzesiuk AK. Epidemiological profile in multiple sclerosis patients, Uberaba, MG, Brazil. ARQUIVOS DE NEURO-PSIQUIATRIA 2011; 69:852. [PMID: 22042201 DOI: 10.1590/s0004-282x2011000600031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
27
|
Aguirre-Cruz L, Flores-Rivera J, De La Cruz-Aguilera DL, Rangel-López E, Corona T. Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 2011; 44:571-5. [PMID: 21875378 DOI: 10.3109/08916934.2011.592887] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Epidemiological and genetic studies suggest that the prevalence, median age of onset, and specific phenotypes of multiple sclerosis (MS) are different in Caucasians and Latino Americans. Recent epidemiological studies indicate an increase in MS prevalence in Latin America (LA), where the south-north gradient of latitude described for Nordic countries does not exist. Analysis of MS epidemiological and specific aspects in LA suggests that susceptibility and clinical behavior of the disease are related to mixtures and admixtures of genes in the population. MS is not present in Amerindians with Mongoloid genes, such as occurs in other pure ethnic groups. Surely, future studies will be carried out to obtain more reliable information. In this review, we contrast and analyze the available data of MS in LA and endemic countries.
Collapse
Affiliation(s)
- Lucinda Aguirre-Cruz
- Laboratory of Neuroimunoendocrinology, National Institute of Neurology and Neurosurgery of Mexico, Mexico DF, Mexico
| | | | | | | | | |
Collapse
|
28
|
|
29
|
Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev 2011; 10:474-81. [PMID: 21440682 DOI: 10.1016/j.autrev.2011.03.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 03/16/2011] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To identify the contribution of HLA-DRB1 alleles to susceptibility or resistance to multiple sclerosis (MS) in Caucasians through a meta-analysis of non-family-based studies. METHODS A systematic review of case-control studies in Caucasians was performed. Studies examining allele or phenotype frequencies were analyzed separately. Odds ratio (OR) and 95% confidence intervals (CIs) were used. We also used the relatively predispositional effect (RPE) method to analyze several allele frequency studies to avoid skewed results due to some strongly associated alleles. RESULTS A total of 5464 cases and 7809 controls from 14 allele frequency studies and a total of 5401 cases and 7538 controls from 23 phenotype frequency studies were analyzed. DRB1*15 was definitely the strongest risk factor for MS (allele group, Pc<0.00013, OR 2.59, 95%CI 2.34-2.87; phenotype group, Pc<0.00013, OR 3.35, 95%CI 2.95-3.80). DRB1*03 frequencies were significantly increased among MS cases in the phenotype group (Pc= 0.0013, OR 1.21, 95%CI 1.09-1.33) but not in the allele group. DRB1*14 and DRB1*07 showed protective effects against MS in both groups (DRB1*14, allele group, Pc<0.00013, OR 0.53, 95%CI 0.42-0.66; phenotype group, Pc<0.00013, OR 0.57, 95%CI 0.45-0.71; DRB1*07, allele group, Pc<0.0026, OR 0.75, 95%CI 0.64-0.87; phenotype group, Pc<0.00013, OR 0.67, 95%CI 0.61-0.73). By RPE method, DRB1*14, and DRB1*07 showed protective effects after excluding DRB1*15 from the analysis. DRB1*03 was significantly higher in MS cases than controls after removing both DRB1*15 and DRB1*14. CONCLUSIONS In Caucasians, we highlighted the definite protective role of HLA-DRB1*14 and DRB1*07 for MS. DRB1*03 is probably the only risk factor for MS besides DRB1*15 and a common genetic foundation for autoimmune disease. Targeting to these alleles may have potential values in prevention or therapy for MS in the specific population.
Collapse
|
30
|
Alves-Leon SV, Veluttini-Pimentel ML, Gouveia ME, Malfetano FR, Gaspareto EL, Alvarenga MP, Frugulhetti I, Quirico-Santos T. Acute disseminated encephalomyelitis: clinical features, HLA DRB1*1501, HLA DRB1*1503, HLA DQA1*0102, HLA DQB1*0602, and HLA DPA1*0301 allelic association study. ARQUIVOS DE NEURO-PSIQUIATRIA 2010; 67:643-51. [PMID: 19722042 DOI: 10.1590/s0004-282x2009000400013] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Accepted: 05/11/2009] [Indexed: 11/21/2022]
Abstract
We evaluated the frequency, demographic, clinical, disability evolution and genetic association of HLA DRB1*1501, DRB1*1503, DQA1*0102, DQB1*0602 and DPA1*0301 alleles in patients diagnosed as acute disseminated encephalomyelitis (ADEM) among a population of CNS demyelinating diseases. Fifteen patients (8.4%) of our series were diagnosed as ADEM. The mean age onset was 35.23 years (range 12 to 77), 53.3% were male and follow-up range was 8.5 to 16 years. Two cases (13.3%) had a preceding infection before neurological symptoms, one presented a parainfectious demyelinating, and one case had been submitted to hepatitis B vaccination four weeks before the clinical onset. The EDSS range was 3.0 to 9.5. Eight patients (53.3%) presented MRI with multiple large lesions. CSF was normal in 73.3%. The severe disability observed at EDSS onset improved in 86.66% patients. The genetic susceptibility for ADEM was significantly associated with the HLA DQB1*0602, DRB1*1501 and DRB1*1503 alleles (<0.05) in monophasic ADEM.
Collapse
|
31
|
Rojas OL, Rojas-Villarraga A, Cruz-Tapias P, Sánchez JL, Suárez-Escudero JC, Patarroyo MA, Anaya JM. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmun Rev 2010; 9:407-13. [DOI: 10.1016/j.autrev.2009.11.001] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Accepted: 11/03/2009] [Indexed: 11/25/2022]
|
32
|
Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, Buzo R, Llamas López L, Rivera Kindel M. Early treatment of multiple sclerosis: a Latin American experts meeting. Mult Scler 2010; 15 Suppl 3:S1-S12. [PMID: 19965556 DOI: 10.1177/1352458509106419] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients.
Collapse
Affiliation(s)
- O Garcea
- Clinical Neuroimmunology and Multiple Sclerosis. Hospital Ramos Mejía, University Center of Neurology, School of Medicine. Buenos Aires University. Urquiza 609 (1221), Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Brum DG, Barreira AA, dos Santos AC, Kaimen-Maciel DR, Matiello M, Costa RM, Deghaide NHS, Costa LS, Louzada-Junior P, Diniz PRB, Comini-Frota ER, Mendes-Junior CT, Donadi EA. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 2009; 16:21-9. [PMID: 19995845 DOI: 10.1177/1352458509350741] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Until recently, neuromyelitis optica (NMO) was considered to be a sub-type of multiple sclerosis (MS), which has a strong predilection for Caucasian populations, whereas NMO is more frequent in non-Caucasian individuals. The objective of this study was to compare the HLA-DRB profile in Brazilian Mulatto patients with NMO spectrum disorders (NMOSDs) with that observed for Mulatto MS patients and healthy Mulatto controls. Twenty seven NMOSD patients (20 women), all seropositive for NMO-IgG, 29 MS patients and 28 Mulatto healthy blood donors were evaluated for HLA-DRB allele groups. HLA-DRB1*03 allele group was overrepresented in NMO patients compared with healthy controls (p = 0.0401; OR = 3.23, 95%CI: 1.07-9.82). In contrast, the HLA-DRB1*15 allele group was overrepresented in Brazilian MS patients (OR = 15.89, 95%CI: 3.51-71.85; p < 0.0001). DRB3 was overrepresented in NMO (p = 0.0064), and DRB5 overrepresented in MS patients (p = 0.0001). The low frequency of HLA-DRB1*15 alleles was associated with the presence of long and central cord lesions at magnetic resonance. In addition, DRB1*15 alleles were associated with the fulfillment of the Barkhof criteria. In conclusion, these results indicate that the DRB profile of NMO patients is different from that observed for MS patients, further corroborating the distinction between NMO and MS.
Collapse
Affiliation(s)
- Doralina Guimaraães Brum
- Division Neurology, Department of Neurosciences, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Ramagopalan SV, Ebers GC. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med 2009; 1:105. [PMID: 19895714 PMCID: PMC2808740 DOI: 10.1186/gm105] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Multiple sclerosis (MS), like many putative autoimmune diseases, has been known to be associated with the human leukocyte antigen (HLA) class II region for more than 3 decades. However, exactly how HLA class II alleles increase the risk of MS is not yet conclusively known. Recent work in large human cohorts has highlighted the fact that nearly all common HLA-DRB1 allelotypes are either positively or negatively associated with the disease, detracting from allele-specific antigen presentation as the sole mechanism of MHC associated disease susceptibility. Here, we put into context recent data on the HLA class II region in MS, including allelic heterogeneity, gene-environment interactions and epigenetics. It is clear that a complete understanding of the epistatic interactions and epigenetic features of this region will be crucial to comprehending disease pathogenesis.
Collapse
Affiliation(s)
- Sreeram V Ramagopalan
- Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7BN, UK
| | | |
Collapse
|
35
|
Alves-Leon SV, Pimentel MLV, Sant'Anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. ARQUIVOS DE NEURO-PSIQUIATRIA 2009; 66:678-84. [PMID: 18949261 DOI: 10.1590/s0004-282x2008000500013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2008] [Accepted: 08/01/2008] [Indexed: 11/22/2022]
Abstract
Neuromyelitis optica (NMO) is an inflammatory, demyelinating disease of the central nervous system characterized by the association of a serious myelitis and unilateral or bilateral optic neuritis. The present study aimed to analyze the immunological parameters of NMO patients with diagnosis established based on Wingerchuck et al. (1999) criteria. Production of IgG and IgA antibodies to antigens of MBP, PLP 95-116, MOG 92-106, and the cytokines interleukin-4 (IL-4) and interferon-gamma (INF-gamma) were assessed by Elisa assay. The cohort was formed by 28 NMO patients and a matched healthy control group. NMO patients had significant high levels of IgG to MOG (p<0.0001), PLP (p=0.0002) and MBP (p<0.0001), and solely IgA to MBP (p<0.0001). INF-gamma (p=0.61) levels were similar to healthy controls. Increased production of IL-4 (p=0.0084) indicates an important role for this cytokine in the activation of Th2 regulatory cells and of the IgA producers B lymphocyte indicating activation of humoral immunity.
Collapse
Affiliation(s)
- Soniza Vieira Alves-Leon
- Neurology Department, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
| | | | | | | | | | | |
Collapse
|
36
|
Pastorino R, Menni C, Barca M, Foco L, Saddi V, Gazzaniga G, Ferrai R, Mascaretti L, Dudbridge F, Berzuini C, Murgia SB, Piras ML, Ticca A, Bitti PP, Bernardinelli L. Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia. PLoS One 2009; 4:e6526. [PMID: 19654877 PMCID: PMC2716537 DOI: 10.1371/journal.pone.0006526] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2008] [Accepted: 07/05/2009] [Indexed: 11/18/2022] Open
Abstract
The human leukocyte antigen (HLA) complex on chromosome 6p21 has been unambiguously associated with multiple sclerosis (MS). The complex features of the HLA region, especially its high genic content, extreme polymorphism, and extensive linkage disequilibrium, has prevented to resolve the nature of HLA association in MS. We performed a family based association study on the isolated population of the Nuoro province (Sardinia) to clarify the role of HLA genes in MS. The main stage of our study involved an analysis of the ancestral haplotypes A2Cw7B58DR2DQ1 and A30Cw5B18DR3DQ2. On the basis of a multiplicative model, the effect of the first haplotype is protective with an odds ratio (OR) = 0.27 (95% confidence interval CI 0.13-0.57), while that of the second is deleterious, OR 1.78 (95% CI 1.26-2.50). We found both class I (A, Cw, B) and class II (DR, DQ) loci to have an effect on MS susceptibility, but we saw that they act independently from each other. We also performed an exploratory analysis on a set of 796 SNPs in the same HLA region. Our study supports the claim that Class I and Class II loci act independently on MS susceptibility and this has a biological explanation. Also, the analysis of SNPs suggests that there are other HLA genes involved in MS, but replication is needed. This opens up new perspective on the study of MS.
Collapse
Affiliation(s)
- Roberta Pastorino
- Dipartimento di Scienze Sanitarie Applicate e Psicocomportamentali, Università di Pavia, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kaushansky N, Altmann DM, Ascough S, David CS, Lassmann H, Ben-Nun A. HLA-DQB1*0602 Determines Disease Susceptibility in a New “Humanized” Multiple Sclerosis Model in HLA-DR15 (DRB1*1501;DQB1*0602) Transgenic Mice. THE JOURNAL OF IMMUNOLOGY 2009; 183:3531-41. [DOI: 10.4049/jimmunol.0900784] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
38
|
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain). J Neurol 2009; 256:1977-88. [DOI: 10.1007/s00415-009-5223-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2009] [Revised: 06/15/2009] [Accepted: 06/17/2009] [Indexed: 10/20/2022]
|
39
|
Abstract
PURPOSE OF REVIEW Multiple sclerosis (MS) is the most common neurological disease affecting young adults. The cause is unknown, but detailed epidemiological and genetic studies have shown a clear inherited component. We review here some of the recent findings of MS genetics with a particular focus on genes of the major histocompatibility complex (MHC). RECENT FINDINGS Recent studies add further complexity to the role of the MHC in MS. Reported MHC associations are complex, involving haplotypes rather than single alleles and may involve epigenetic mechanisms and other modulators of gene expression. MHC class II haplotypes display a hierarchy of risks, including protective effects and epistatic interactions, which together dwarf any non-MHC genetic effect. Genes in the MHC region have been shown to influence disease severity, display parent-of-origin effects and interact with a major environmental candidate for MS, vitamin D. SUMMARY The MHC class II association with MS is not as straightforward as previously thought. A complete understanding of the epistatic interactions and epigenetic features of this region will be important to understand disease pathogenesis and likely aid the discovery of new therapeutics.
Collapse
|
40
|
Ghabaee M, Bayati A, Amri Saroukolaei S, Sahraian MA, Sanaati MH, Karimi P, Houshmand M, Sadeghian H, Hashemi Chelavi L. Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis. Cell Mol Neurobiol 2009; 29:109-14. [PMID: 18726686 PMCID: PMC11505791 DOI: 10.1007/s10571-008-9302-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2008] [Accepted: 07/31/2008] [Indexed: 10/21/2022]
Abstract
Multiple sclerosis (MS) is prototype of inflammatory demyelinating disease of the central nervous system .The etiology of MS remains unclear, but according to current data the disease develops in genetically susceptible individuals and may require additional environmental triggers. The human leukocyte antigen (HLA) class II alleles (DRB1*1501, DQA1*0102, DQB1*0602) may have the strongest genetic effect in MS. In this study, the role of these alleles were investigated in 183 Iranian patients with multiple sclerosis and compared with 100 healthy individuals. HLA typing for DRB1*1501, DQA1*0102, DQB1*0602 was performed by polymerase chain reaction (PCR) amplification with sequence-specific primers (PCR-SSP) method. The results show that, HLA DR B1*1501 was significantly more frequent among MS patients (46% vs. 20%, PV = 0.0006) but DQA1*0102 haplotype was negatively associated with MS (30% vs. 50%, PV = 0.0049) and no significant association was found with DQB1*0602 and MS patients in comparison with control group (24% and 30%, PV = 0.43). No significant correlation was observed among these alleles with sex, type of disease; initial symptoms, expanded disability status scale (EDSS), as well as age at onset and familial MS. This study therefore indicates that there is no association of above HLA haplotypes with clinical presentation, disease duration, and disability in Iranian patients with MS which is in line with other previous studies in different ethnic groups.
Collapse
Affiliation(s)
- Mojdeh Ghabaee
- Department of Neurology, Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Adoni T, Lino AMM, Marchiori PE, Kok F, Callegaro D. Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. ARQUIVOS DE NEURO-PSIQUIATRIA 2008; 66:295-7. [DOI: 10.1590/s0004-282x2008000300001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2007] [Accepted: 04/24/2008] [Indexed: 11/22/2022]
Abstract
OBJECTIVE: To determine the seroprevalence of neuromyelitis optica antibody (NMO)-IgG in Brazilian patients with clinical diagnosis of relapsing neuromyelitis optica, also known as Devic's disease. METHOD: We determined NMO-IgG titers in 28 patients (25 of them females) that fulfilled the 1999 NMO diagnostic criteria proposed by Wingerchuk et al. RESULTS: NMO-IgG was detected in 18 NMO patients (64.3%). CONCLUSION: Our results showed that seroprevalence of NMO-IgG in Brazilian NMO patients was similar to the observed in other studies.
Collapse
|
42
|
Alves-Leon SV, Malfetano FR, Pimentel MLV, Estrada CLD, Pereira VCSR, Liem AM, Novis SAP. Multiple sclerosis outcome and morbi-mortality of a Brazilian cohort patients. ARQUIVOS DE NEURO-PSIQUIATRIA 2008; 66:671-7. [DOI: 10.1590/s0004-282x2008000500012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2008] [Accepted: 07/25/2008] [Indexed: 11/21/2022]
Abstract
We studied the clinical and evolution characteristics of multiple sclerosis (MS) patients followed since the onset of HUCFF/UFRJ in 1978. The diagnosis of MS was based on Poser's et al. and MC Donald's et al. criteria. From 188 patients, 122 were included. Eighty-five were females. The mean age onset was 32.2 years-old (range 6.0 to 61.0±10.3), mainly Caucasians (82/67%). The relapsing-remitting course (MSRR) was more frequent (106/86.8%). Monosymptomatic onset was significantly more frequent in Caucasians than in Afro-Brazilians (p<0.05). Seventeen patients had benign form of MS and these patients presented association with MSRR when compared with severe form (p=0.01). The mortality rate was 2.12% (4 patients died). This study was similar to other Brazilian series with regard to sex and age, and lack of correlation between EDSS and number of relapses; it confirmed south-southeast African-descendants gradient distribution and association between first mono-symptomatic relapses and Caucasian; we found lower frequency of benign forms.
Collapse
Affiliation(s)
- Soniza Vieira Alves-Leon
- Universidade Federal do Estado do Rio de Janeiro; UNIRIO; Universidade Federal do Rio de Janeiro, Brazil; UFRJ
| | | | | | | | | | | | | |
Collapse
|